EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Second‐line treatment of pediatric patients with relapsed rhabdomyosarcoma adapted to initial risk stratification: Data of the European Soft Tissue Sarcoma Registry (SoTiSaR)

Amadeus T Heinz iD, Martin Ebinger iD, Anton Schönstein, Jörg Fuchs, Beate Timmermann, Guido Seitz, Christian Vokuhl iD, Marc W Münter, Kristian W Pajtler, Sabine Stegmaier iD, Thekla von Kalle, Christian P Kratz und 6 weitere

Pediatric Blood & Cancer · 2023

DOI: 10.1002/pbc.30363 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2023. Verfasst von Amadeus T Heinz und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Hematology and Oncology, University Children´s Hospital Tuebingen, Tuebingen, Germany. Hauptthemen laut MEDLINE: Rhabdomyosarcoma, Sarcoma, Soft Tissue Neoplasms, Polyketides. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Outcome of relapsed disease of localized rhabdomyosarcoma remains poor. An individual treatment approach considering the initial systemic treatment and risk group was included in the Cooperative Weichteilsarkom Studiengruppe (CWS) Guidance.

Methods

Second‐line chemotherapy (sCHT) ACCTTIVE based on anthracyclines (adriamycin, carboplatin, cyclophosphamide, topotecan, vincristine, etoposide) was recommended for patients with initial low‐ (LR), standard‐ (SR), and high‐risk (HR) group after initial treatment without anthracyclines. TECC (topotecan, etoposide, carboplatin, cyclophosphamide) was recommended after initial anthracycline‐based regimen in the very high‐risk (VHR) group. Data of patients with relapse ( n = 68) registered in the European Soft Tissue Sarcoma Registry SoTiSaR (2009–2018) were retrospectively analyzed.

Results

Patients of initial LR ( n = 2), SR ( n = 16), HR ( n = 41), and VHR ( n = 9) group relapsed. sCHT consisted of ACCTTIVE ( n = 36), TECC ( n = 12), or other ( n = 15). Resection was performed in 40/68 (59%) patients and/or radiotherapy in 47/68 (69%). Initial risk stratification, pattern/time to relapse, and achievement of second complete remission were significant prognostic factors. Microscopically incomplete resection with additional radiotherapy was not inferior to microscopically complete resection ( p = .17). The 5‐year event‐free survival (EFS) and overall survival (OS) were 26% (±12%) and 31% (±14%). The 5‐year OS of patients with relapse of SR, HR, and VHR groups was 80% (±21%), 20% (±16%), and 13% (±23%, p = .008), respectively.

Conclusion

Adapted systemic treatment of relapsed disease considering the initial risk group and initial treatment is reasonable. New treatment options are needed for patients of initial HR and VHR groups.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RhabdomyosarcomaSarcomaSoft Tissue NeoplasmsPolyketidesHumansChildEtoposideCarboplatinRetrospective StudiesTopotecanCyclophosphamideChronic DiseaseAnthracyclinesRecurrenceAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

Soft Tissue Sarcoma Registry (SoTiSaR)localized diseaserelapsed diseaserhabdomyosarcomasecond-line chemotherapy

Substanzen

EtoposideCarboplatinTopotecanCyclophosphamideAnthracyclinesPolyketides

Autor:innen und Institutionen

  • Department of Pediatric Hematology and Oncology, University Children´s Hospital Tuebingen, Tuebingen, Germany.
  • Network Aging Research, Heidelberg University, Heidelberg, Germany.
  • Department of Pediatric Surgery and Urology, University Children's Hospital Tuebingen, Tuebingen, Germany.
  • Department of Particle Therapy, West German Proton Therapy Centre Essen (WPE), University Medical Center Essen, West German Cancer Center (WTZ), German Cancer Consortium (DKTK), Essen, Germany.
  • Department of Pediatric Surgery, University Hospital Giessen-Marburg, Marburg, Germany.
  • Section of Pediatric Pathology, University Hospital Bonn, Bonn, Germany.

ORCID-Profile: Amadeus T Heinz, Martin Ebinger, Christian Vokuhl, Sabine Stegmaier, Jochen Rößler, Ewa Koscielniak, Monika Sparber-Sauer

Zitieren

APA

Heinz, A. T., Ebinger, M., Schönstein, A., Fuchs, J., Timmermann, B., Seitz, G., Vokuhl, C., Münter, M. W., Pajtler, K. W., Stegmaier, S., von Kalle, T., Kratz, C. P., Rößler, J., Ljungman, G., Klingebiel, T., Koscielniak, E., Sparber-Sauer, M., & Cooperative Weichteilsarkom Studiengruppe (CWS) (2023). Second‐line treatment of pediatric patients with relapsed rhabdomyosarcoma adapted to initial risk stratification: Data of the European Soft Tissue Sarcoma Registry (SoTiSaR). Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30363

Vancouver

Heinz AT, Ebinger M, Schönstein A, Fuchs J, Timmermann B, Seitz G, et al. Second‐line treatment of pediatric patients with relapsed rhabdomyosarcoma adapted to initial risk stratification: Data of the European Soft Tissue Sarcoma Registry (SoTiSaR). Pediatric Blood & Cancer. 2023. doi:10.1002/pbc.30363

BibTeX
@article{Heinz2023,
  author = {Heinz, Amadeus T and Ebinger, Martin and Schönstein, Anton and Fuchs, Jörg and Timmermann, Beate and Seitz, Guido and Vokuhl, Christian and Münter, Marc W and Pajtler, Kristian W and Stegmaier, Sabine and von Kalle, Thekla and Kratz, Christian P and Rößler, Jochen and Ljungman, Gustaf and Klingebiel, Thomas and Koscielniak, Ewa and Sparber-Sauer, Monika and Cooperative Weichteilsarkom Studiengruppe (CWS), Cooperative Weichteilsarkom Studiengruppe (CWS)},
  title = {Second‐line treatment of pediatric patients with relapsed rhabdomyosarcoma adapted to initial risk stratification: Data of the European Soft Tissue Sarcoma Registry (SoTiSaR)},
  journal = {Pediatric Blood & Cancer},
  year = {2023},
  doi = {10.1002/pbc.30363}
}
Kostenlos starten →